,paragraph,value,label,name,type,company,sent,entity,entity_type_ext,sentence,phrases,qa_temp,key,score,question,answer,GPT3 Responses
0,"The aggregate market value of the voting and non voting common stock held by non affiliates of the registrant was approximately $63,344,000,000, computed by reference to the closing sales price of the stock on NASDAQ on June 30, 2020, the last trading day of the registrant's most recently completed second fiscal quarter. For purposes of this calculation only, the registrant has assumed that all of its directors and executive officers, and no other persons, are its affiliates. This determination of affiliate status is not necessarily a determination for other purposes.","63,344,000,000",['Entity Public Float'],dei_EntityPublicFloat,monetaryItemType,regn,"The aggregate market value of the voting and non voting common stock held by non affiliates of the registrant was approximately $63,344,000,000, computed by reference to the closing sales price of the stock on NASDAQ on June 30, 2020, the last trading day of the registrant's most recently completed second fiscal quarter.","approximately $63,344,000,000",MONEY,"The aggregate market value of the voting and non voting common stock held by non affiliates of the registrant was approximately $63,344,000,000, computed by reference to the closing sales price of the stock on NASDAQ on June 30, 2020, the last trading day of the registrant's most recently completed second fiscal quarter.","['aggregate market value', 'non affiliates of registrant', 'reference to closing sales price', 'closing sales price of stock', 'stock on NASDAQ', 'reference on June', 'last trading day of completed second fiscal quarter', 'aggregate market value', 'common stock', 'non affiliates', 'sales price']","['The aggregate market value of the voting and non voting common stock', 0.27913036942481995, 'What is approximately $63,344,000,000 ?', 'The aggregate market value of the voting and non voting common stock']",The aggregate market value of the voting and non voting common stock,0.2791303694248199,"What is approximately $63,344,000,000 ?",The aggregate market value of the voting and non voting common stock,the aggregate market value of the voting and non voting common stock held by non affiliates of the registrant
1,"Preferred Stock, $.01 par value; 30,000,000 shares authorized; issued and outstanding none","30,000,000","['Preferred Stock, shares authorized']",us-gaap_PreferredStockSharesAuthorized,sharesItemType,regn,"Preferred Stock, $.01 par value; 30,000,000 shares authorized; issued and outstanding   none","30,000,000",CARDINAL,"Preferred Stock, $.01 par value; 30,000,000 shares authorized; issued and outstanding   none",[],"['shares authorized', 0.9482001066207886, 'What is 30,000,000 ?', 'shares authorized']",shares authorized,0.9482001066207886,"What is 30,000,000 ?",shares authorized,Preferred Stock shares authorized
2,"Preferred Stock, $.01 par value; 30,000,000 shares authorized; issued and outstanding none","30,000,000","['Preferred Stock, shares authorized']",us-gaap_PreferredStockSharesAuthorized,sharesItemType,regn,"Preferred Stock, $.01 par value; 30,000,000 shares authorized; issued and outstanding   none","30,000,000",CARDINAL,"Preferred Stock, $.01 par value; 30,000,000 shares authorized; issued and outstanding   none",[],"['shares authorized', 0.9482001066207886, 'What is 30,000,000 ?', 'shares authorized']",shares authorized,0.9482001066207886,"What is 30,000,000 ?",shares authorized,Preferred Stock shares authorized
3,"Class A Stock, convertible, $.001 par value; 40,000,000 shares authorized; shares issued and outstanding 1,848,970 in 2020 and 2019","40,000,000","['Common Stock, shares authorized']",us-gaap_CommonStockSharesAuthorized,sharesItemType,regn,"Class A Stock, convertible, $.001 par value; 40,000,000 shares authorized; shares issued and outstanding   1,848,970 in 2020 and 2019","40,000,000",CARDINAL,"Class A Stock, convertible, $.001 par value; 40,000,000 shares authorized; shares issued and outstanding   1,848,970 in 2020 and 2019",['shares'],"['shares authorized', 0.9702397584915161, 'What is 40,000,000 ?', 'shares authorized']",shares authorized,0.970239758491516,"What is 40,000,000 ?",shares authorized,Class A Stock
4,"Class A Stock, convertible, $.001 par value; 40,000,000 shares authorized; shares issued and outstanding 1,848,970 in 2020 and 2019","40,000,000","['Common Stock, shares authorized']",us-gaap_CommonStockSharesAuthorized,sharesItemType,regn,"Class A Stock, convertible, $.001 par value; 40,000,000 shares authorized; shares issued and outstanding   1,848,970 in 2020 and 2019","40,000,000",CARDINAL,"Class A Stock, convertible, $.001 par value; 40,000,000 shares authorized; shares issued and outstanding   1,848,970 in 2020 and 2019",['shares'],"['shares authorized', 0.9702397584915161, 'What is 40,000,000 ?', 'shares authorized']",shares authorized,0.970239758491516,"What is 40,000,000 ?",shares authorized,Class A Stock
5,"Class A Stock, convertible, $.001 par value; 40,000,000 shares authorized; shares issued and outstanding 1,848,970 in 2020 and 2019","1,848,970","['Common Stock, shares issued']",us-gaap_CommonStockSharesIssued,sharesItemType,regn,"Class A Stock, convertible, $.001 par value; 40,000,000 shares authorized; shares issued and outstanding   1,848,970 in 2020 and 2019","1,848,970",CARDINAL,"Class A Stock, convertible, $.001 par value; 40,000,000 shares authorized; shares issued and outstanding   1,848,970 in 2020 and 2019",['shares'],"['outstanding', 0.9735630750656128, 'What is 1,848,970 ?', 'outstanding']",outstanding,0.9735630750656128,"What is 1,848,970 ?",outstanding,"Class A Stock, convertible, $.001 par value; 40,000,000 shares authorized; shares issued and outstanding"
6,"Class A Stock, convertible, $.001 par value; 40,000,000 shares authorized; shares issued and outstanding 1,848,970 in 2020 and 2019","1,848,970","['Common Stock, shares outstanding']",us-gaap_CommonStockSharesOutstanding,sharesItemType,regn,"Class A Stock, convertible, $.001 par value; 40,000,000 shares authorized; shares issued and outstanding   1,848,970 in 2020 and 2019","1,848,970",CARDINAL,"Class A Stock, convertible, $.001 par value; 40,000,000 shares authorized; shares issued and outstanding   1,848,970 in 2020 and 2019",['shares'],"['outstanding', 0.9735630750656128, 'What is 1,848,970 ?', 'outstanding']",outstanding,0.9735630750656128,"What is 1,848,970 ?",outstanding,Class A Stock convertible shares authorized issued and outstanding
7,"Class A Stock, convertible, $.001 par value; 40,000,000 shares authorized; shares issued and outstanding 1,848,970 in 2020 and 2019","1,848,970","['Common Stock, shares outstanding']",us-gaap_CommonStockSharesOutstanding,sharesItemType,regn,"Class A Stock, convertible, $.001 par value; 40,000,000 shares authorized; shares issued and outstanding   1,848,970 in 2020 and 2019","1,848,970",CARDINAL,"Class A Stock, convertible, $.001 par value; 40,000,000 shares authorized; shares issued and outstanding   1,848,970 in 2020 and 2019",['shares'],"['outstanding', 0.9735630750656128, 'What is 1,848,970 ?', 'outstanding']",outstanding,0.9735630750656128,"What is 1,848,970 ?",outstanding,"Class A Stock, convertible, $.001 par value"
8,"Class A Stock, convertible, $.001 par value; 40,000,000 shares authorized; shares issued and outstanding 1,848,970 in 2020 and 2019","1,848,970","['Common Stock, shares issued']",us-gaap_CommonStockSharesIssued,sharesItemType,regn,"Class A Stock, convertible, $.001 par value; 40,000,000 shares authorized; shares issued and outstanding   1,848,970 in 2020 and 2019","1,848,970",CARDINAL,"Class A Stock, convertible, $.001 par value; 40,000,000 shares authorized; shares issued and outstanding   1,848,970 in 2020 and 2019",['shares'],"['outstanding', 0.9735630750656128, 'What is 1,848,970 ?', 'outstanding']",outstanding,0.9735630750656128,"What is 1,848,970 ?",outstanding,Class A Stock convertible
9,"Common Stock, $.001 par value; 320,000,000 shares authorized; shares issued 121,533,460 in 2020 and 113,288,103 in 2019","320,000,000","['Common Stock, shares authorized']",us-gaap_CommonStockSharesAuthorized,sharesItemType,regn,"Common Stock, $.001 par value; 320,000,000 shares authorized; shares issued   121,533,460 in 2020 and 113,288,103 in 2019","320,000,000",CARDINAL,"Common Stock, $.001 par value; 320,000,000 shares authorized; shares issued   121,533,460 in 2020 and 113,288,103 in 2019",['Common Stock'],"['shares authorized', 0.9418449997901917, 'What is 320,000,000 ?', 'shares authorized']",shares authorized,0.9418449997901917,"What is 320,000,000 ?",shares authorized,shares authorized
10,"Common Stock, $.001 par value; 320,000,000 shares authorized; shares issued 121,533,460 in 2020 and 113,288,103 in 2019","320,000,000","['Common Stock, shares authorized']",us-gaap_CommonStockSharesAuthorized,sharesItemType,regn,"Common Stock, $.001 par value; 320,000,000 shares authorized; shares issued   121,533,460 in 2020 and 113,288,103 in 2019","320,000,000",CARDINAL,"Common Stock, $.001 par value; 320,000,000 shares authorized; shares issued   121,533,460 in 2020 and 113,288,103 in 2019",['Common Stock'],"['shares authorized', 0.9418449997901917, 'What is 320,000,000 ?', 'shares authorized']",shares authorized,0.9418449997901917,"What is 320,000,000 ?",shares authorized,shares authorized
11,"Common Stock, $.001 par value; 320,000,000 shares authorized; shares issued 121,533,460 in 2020 and 113,288,103 in 2019","121,533,460","['Common Stock, shares issued']",us-gaap_CommonStockSharesIssued,sharesItemType,regn,"Common Stock, $.001 par value; 320,000,000 shares authorized; shares issued   121,533,460 in 2020 and 113,288,103 in 2019","121,533,460",CARDINAL,"Common Stock, $.001 par value; 320,000,000 shares authorized; shares issued   121,533,460 in 2020 and 113,288,103 in 2019",['Common Stock'],"['shares', 0.902719259262085, 'What is 121,533,460 ?', 'shares']",shares,0.902719259262085,"What is 121,533,460 ?",shares,shares issued in 2020
12,"Common Stock, $.001 par value; 320,000,000 shares authorized; shares issued 121,533,460 in 2020 and 113,288,103 in 2019","113,288,103","['Common Stock, shares issued']",us-gaap_CommonStockSharesIssued,sharesItemType,regn,"Common Stock, $.001 par value; 320,000,000 shares authorized; shares issued   121,533,460 in 2020 and 113,288,103 in 2019","113,288,103",CARDINAL,"Common Stock, $.001 par value; 320,000,000 shares authorized; shares issued   121,533,460 in 2020 and 113,288,103 in 2019",['Common Stock'],"['', 0, '', '']",,0.0,,,common stock shares authorized issued
13,"Treasury Stock, at cost; 16,431,520 shares in 2020 and 4,860,123 shares in 2019","16,431,520",['Treasury Stock'],us-gaap_TreasuryStockShares,sharesItemType,regn,"Treasury Stock, at cost; 16,431,520 shares in 2020 and 4,860,123 shares in 2019","16,431,520",CARDINAL,"Treasury Stock, at cost; 16,431,520 shares in 2020 and 4,860,123 shares in 2019","['shares in shares', 'shares']","['shares', 0.24667395651340485, 'how many shares ?', '16,431,520']",shares,0.2466739565134048,how many shares ?,"16,431,520",Treasury Stock at cost
14,"Treasury Stock, at cost; 16,431,520 shares in 2020 and 4,860,123 shares in 2019","4,860,123",['Treasury Stock'],us-gaap_TreasuryStockShares,sharesItemType,regn,"Treasury Stock, at cost; 16,431,520 shares in 2020 and 4,860,123 shares in 2019","4,860,123",CARDINAL,"Treasury Stock, at cost; 16,431,520 shares in 2020 and 4,860,123 shares in 2019","['shares in shares', 'shares']","['shares in shares', 0.5884348154067993, 'how many shares in shares ?', '4,860,123']",shares in shares,0.5884348154067993,how many shares in shares ?,"4,860,123",Treasury Stock at cost
15,"The Company operates in one business segment, which includes all activities related to the discovery, development, and commercialization of medicines for the treatment of serious diseases. The Company's business is subject to certain risks including, but not limited to, uncertainties relating to conducting research activities, product development, obtaining regulatory approvals, competition, and obtaining and enforcing patents.",one,['Number of business segments'],us-gaap_NumberOfReportableSegments,integerItemType,regn,"The Company operates in one business segment, which includes all activities related to the discovery, development, and commercialization of medicines for the treatment of serious diseases.",one,CARDINAL,"The Company operates in one business segment, which includes all activities related to the discovery, development, and commercialization of medicines for the treatment of serious diseases.","['commercialization of medicines', 'medicines for treatment', 'treatment of serious diseases', 'business segment', 'serious diseases']","['business segment', 0.9009377360343933, 'how many business segment ?', 'one']",business segment,0.9009377360343932,how many business segment ?,one,The Company operates in one business segment
16,"We adopted Accounting Standards Codification (""ASC"") 842, Leases, on January 1, 2019 (the ""effective date"") and used the effective date as our date of initial application. See Note 10. The new standard requires a lessee to recognize on its balance sheet (for both finance and operating leases) a liability for future lease payments and a right of use asset representing its right to use the underlying asset over the lease term. We elected the practical expedients upon transition, which permitted companies to not reassess lease identification, classification, and initial direct costs under the new standard for leases that commenced prior to the effective date. Upon adoption of the new standard, we recognized right of use assets of $33.2 million related to operating leases as of January 1, 2019. The impact of adopting the standard for the facilities that we had historically applied build to suit and capital lease accounting was not material to our Consolidated Financial Statements. Prior period amounts were not adjusted in connection with the adoption of this standard.",33.2,['Right of use asset'],us-gaap_OperatingLeaseRightOfUseAsset,monetaryItemType,regn,"Upon adoption of the new standard, we recognized right of use assets of $33.2 million related to operating leases as of January 1, 2019.",$33.2 million,MONEY,"Upon adoption of the new standard, we recognized right of use assets of $33.2 million related to operating leases as of January 1, 2019.","['adoption of new standard', 'use assets', 'new standard', 'use assets', 'operating leases']","['operating leases', 0.5514190196990967, 'What is $33.2 million ?', 'operating leases']",operating leases,0.5514190196990967,What is $33.2 million ?,operating leases,Right of use assets
17,"We adopted ASC 606, Revenue from Contracts with Customers, as of January 1, 2018. The Company adopted the standard using the modified retrospective method, and thus recognized a cumulative effect adjustment to reduce Retained earnings and increase Deferred revenue on January 1, 2018 by $143.4 million, net of tax.",143.4,['Deferred revenue'],us-gaap_ContractWithCustomerLiability,monetaryItemType,regn,"The Company adopted the standard using the modified retrospective method, and thus recognized a cumulative effect adjustment to reduce Retained earnings and increase Deferred revenue on January 1, 2018 by $143.4 million, net of tax.",$143.4 million,MONEY,"The Company adopted the standard using the modified retrospective method, and thus recognized a cumulative effect adjustment to reduce Retained earnings and increase Deferred revenue on January 1, 2018 by $143.4 million, net of tax.","['net of tax', 'retrospective method', 'cumulative effect adjustment', 'Retained earnings', 'Deferred revenue']","['net of tax', 0.9873313307762146, 'what is net of tax ?', '$143.4 million']",net of tax,0.9873313307762146,what is net of tax ?,$143.4 million,Cumulative effect adjustment
18,"We adopted ASC 606, Revenue from Contracts with Customers, as of January 1, 2018. The Company adopted the standard using the modified retrospective method, and thus recognized a cumulative effect adjustment to reduce Retained earnings and increase Deferred revenue on January 1, 2018 by $143.4 million, net of tax.",143.4,"['Retained Earnings', 'Retained earnings']",us-gaap_RetainedEarningsAccumulatedDeficit,monetaryItemType,regn,"The Company adopted the standard using the modified retrospective method, and thus recognized a cumulative effect adjustment to reduce Retained earnings and increase Deferred revenue on January 1, 2018 by $143.4 million, net of tax.",$143.4 million,MONEY,"The Company adopted the standard using the modified retrospective method, and thus recognized a cumulative effect adjustment to reduce Retained earnings and increase Deferred revenue on January 1, 2018 by $143.4 million, net of tax.","['net of tax', 'retrospective method', 'cumulative effect adjustment', 'Retained earnings', 'Deferred revenue']","['net of tax', 0.9873313307762146, 'what is net of tax ?', '$143.4 million']",net of tax,0.9873313307762146,what is net of tax ?,$143.4 million,Cumulative effect adjustment
19,"Concentrations of credit risk with respect to accounts receivable are significant. The Company has a concentration of credit risk associated with the receivables due from its collaborators Bayer, Sanofi, and Teva. The Company is also subject to credit risk with accounts receivable from its product sales to its customers. As of December 31, 2020 and 2019, three individual customers accounted for 93% and 97%, respectively, of the Company's net trade accounts receivable balances. The Company has contractual payment terms with each of its collaborators and customers, and the Company monitors their financial performance and credit worthiness so that it can properly assess and respond to any changes in their credit profile. As of December 31, 2020 and 2019, there were no write offs and allowances of accounts receivable related to credit risk for our collaborators or customers.",93,"['Concentration risk, percentage']",us-gaap_ConcentrationRiskPercentage1,percentItemType,regn,"As of December 31, 2020 and 2019, three individual customers accounted for 93% and 97%, respectively, of the Company's net trade accounts receivable balances.",93% and 97%,PERCENT,"As of December 31, 2020 and 2019, three individual customers accounted for 93% and 97%, respectively, of the Company's net trade accounts receivable balances.","['individual customers', 'receivable balances']","['net trade accounts receivable balances', 0.1881149858236313, 'What is 93% and 97% ?', 'net trade accounts receivable balances']",net trade accounts receivable balances,0.1881149858236313,What is 93% and 97% ?,net trade accounts receivable balances,Net trade accounts receivable balances
20,"Concentrations of credit risk with respect to accounts receivable are significant. The Company has a concentration of credit risk associated with the receivables due from its collaborators Bayer, Sanofi, and Teva. The Company is also subject to credit risk with accounts receivable from its product sales to its customers. As of December 31, 2020 and 2019, three individual customers accounted for 93% and 97%, respectively, of the Company's net trade accounts receivable balances. The Company has contractual payment terms with each of its collaborators and customers, and the Company monitors their financial performance and credit worthiness so that it can properly assess and respond to any changes in their credit profile. As of December 31, 2020 and 2019, there were no write offs and allowances of accounts receivable related to credit risk for our collaborators or customers.",97,"['Concentration risk, percentage']",us-gaap_ConcentrationRiskPercentage1,percentItemType,regn,"As of December 31, 2020 and 2019, three individual customers accounted for 93% and 97%, respectively, of the Company's net trade accounts receivable balances.",93% and 97%,PERCENT,"As of December 31, 2020 and 2019, three individual customers accounted for 93% and 97%, respectively, of the Company's net trade accounts receivable balances.","['individual customers', 'receivable balances']","['net trade accounts receivable balances', 0.1881149858236313, 'What is 93% and 97% ?', 'net trade accounts receivable balances']",net trade accounts receivable balances,0.1881149858236313,What is 93% and 97% ?,net trade accounts receivable balances,the Company's net trade accounts receivable balances
21,"In agreements involving multiple goods or services promised to be transferred to our collaborator, we must assess, at the inception of the contract, whether each promise represents a separate obligation (i.e., is ""distinct""), or whether such promises should be combined as a single unit of account. When we have a combined unit of account which includes a license and providing research and development services to our collaborator, recognition of up front payments and development milestones earned from our collaborator is deferred (as a liability) and recognized over the development period (i.e., over time). In arrangements where we satisfy our obligation(s) during the development phase over time, we recognize amounts initially deferred over time typically using an input method on the basis of our research and development costs incurred relative to the total expected cost which determines the extent of our progress toward completion. We review our estimates each period and make revisions to such estimates as necessary. We recognized other operating income in connection with up front and development milestones earned, for which we used an input method, of $276.7 million and $207.2 million for the years ended December 31, 2020 and 2019, respectively.",276.7,['Up front and development milestone revenue recognized'],regn_UpFrontAndDevelopmentMilestoneRevenueRecognized,monetaryItemType,regn,"We recognized other operating income in connection with up front and development milestones earned, for which we used an input method, of $276.7 million and $207.2 million for the years ended December 31, 2020 and 2019, respectively.",$276.7 million,MONEY,"We recognized other operating income in connection with up front and development milestones earned, for which we used an input method, of $276.7 million and $207.2 million for the years ended December 31, 2020 and 2019, respectively.","['connection with milestones', 'other income', 'input method']","['operating income', 0.29466718435287476, 'What is $276.7 million ?', 'operating income']",operating income,0.2946671843528747,What is $276.7 million ?,operating income,"Operating income up front

Entity: 
$207.2 million 
Phrase: 
Development milestones earned"
22,"In agreements involving multiple goods or services promised to be transferred to our collaborator, we must assess, at the inception of the contract, whether each promise represents a separate obligation (i.e., is ""distinct""), or whether such promises should be combined as a single unit of account. When we have a combined unit of account which includes a license and providing research and development services to our collaborator, recognition of up front payments and development milestones earned from our collaborator is deferred (as a liability) and recognized over the development period (i.e., over time). In arrangements where we satisfy our obligation(s) during the development phase over time, we recognize amounts initially deferred over time typically using an input method on the basis of our research and development costs incurred relative to the total expected cost which determines the extent of our progress toward completion. We review our estimates each period and make revisions to such estimates as necessary. We recognized other operating income in connection with up front and development milestones earned, for which we used an input method, of $276.7 million and $207.2 million for the years ended December 31, 2020 and 2019, respectively.",207.2,['Up front and development milestone revenue recognized'],regn_UpFrontAndDevelopmentMilestoneRevenueRecognized,monetaryItemType,regn,"We recognized other operating income in connection with up front and development milestones earned, for which we used an input method, of $276.7 million and $207.2 million for the years ended December 31, 2020 and 2019, respectively.",$207.2 million,MONEY,"We recognized other operating income in connection with up front and development milestones earned, for which we used an input method, of $276.7 million and $207.2 million for the years ended December 31, 2020 and 2019, respectively.","['connection with milestones', 'other income', 'input method']","['', 0, '', '']",,0.0,,,We recognized other operating income
23,"The Company is party to a global, strategic collaboration with Sanofi to research, develop, and commercialize fully human monoclonal antibodies (the ""Antibody Collaboration""), which currently consists of Dupixent, Kevzara, and itepekimab. Under the terms of the Antibody License and Collaboration Agreement (""LCA""), Sanofi is generally responsible for funding 80%–100% of agreed upon development costs. We are obligated to reimburse Sanofi for 30%–50% of worldwide development expenses that were funded by Sanofi (collectively, the ""development balance"") based on our share of collaboration profits from commercialization of collaboration products. However, we are only required to apply 10% of our share of the profits from the Antibody Collaboration in any calendar quarter to reimburse Sanofi for these development costs. The Company's contingent reimbursement obligation to Sanofi under the Antibody Collaboration was approximately $3.103 billion as of December 31, 2020.",80,['Percentage of trial costs required to be funded by collaborating party'],regn_PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty,percentItemType,regn,"Under the terms of the Antibody License and Collaboration Agreement (""LCA""), Sanofi is generally responsible for funding 80%–100% of agreed upon development costs.",80%–100%,PERCENT,"Under the terms of the Antibody License and Collaboration Agreement , Sanofi is generally responsible for funding 80%–100% of agreed upon development costs.","['terms of Antibody Agreement', 'development costs']","['agreed upon development costs', 0.9350182414054871, 'What is 80%–100% ?', 'agreed upon development costs']",agreed upon development costs,0.9350182414054872,What is 80%–100% ?,agreed upon development costs,Agreed upon development costs
24,"The Company is party to a global, strategic collaboration with Sanofi to research, develop, and commercialize fully human monoclonal antibodies (the ""Antibody Collaboration""), which currently consists of Dupixent, Kevzara, and itepekimab. Under the terms of the Antibody License and Collaboration Agreement (""LCA""), Sanofi is generally responsible for funding 80%–100% of agreed upon development costs. We are obligated to reimburse Sanofi for 30%–50% of worldwide development expenses that were funded by Sanofi (collectively, the ""development balance"") based on our share of collaboration profits from commercialization of collaboration products. However, we are only required to apply 10% of our share of the profits from the Antibody Collaboration in any calendar quarter to reimburse Sanofi for these development costs. The Company's contingent reimbursement obligation to Sanofi under the Antibody Collaboration was approximately $3.103 billion as of December 31, 2020.",100,['Percentage of trial costs required to be funded by collaborating party'],regn_PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty,percentItemType,regn,"Under the terms of the Antibody License and Collaboration Agreement (""LCA""), Sanofi is generally responsible for funding 80%–100% of agreed upon development costs.",80%–100%,PERCENT,"Under the terms of the Antibody License and Collaboration Agreement , Sanofi is generally responsible for funding 80%–100% of agreed upon development costs.","['terms of Antibody Agreement', 'development costs']","['agreed upon development costs', 0.9350182414054871, 'What is 80%–100% ?', 'agreed upon development costs']",agreed upon development costs,0.9350182414054872,What is 80%–100% ?,agreed upon development costs,Development costs
25,"The Company is party to a global, strategic collaboration with Sanofi to research, develop, and commercialize fully human monoclonal antibodies (the ""Antibody Collaboration""), which currently consists of Dupixent, Kevzara, and itepekimab. Under the terms of the Antibody License and Collaboration Agreement (""LCA""), Sanofi is generally responsible for funding 80%–100% of agreed upon development costs. We are obligated to reimburse Sanofi for 30%–50% of worldwide development expenses that were funded by Sanofi (collectively, the ""development balance"") based on our share of collaboration profits from commercialization of collaboration products. However, we are only required to apply 10% of our share of the profits from the Antibody Collaboration in any calendar quarter to reimburse Sanofi for these development costs. The Company's contingent reimbursement obligation to Sanofi under the Antibody Collaboration was approximately $3.103 billion as of December 31, 2020.",30,['Percentage of repayment of development balance out of profits'],regn_PercentageOfRepaymentOfDevelopmentBalanceOutOfProfits,percentItemType,regn,"We are obligated to reimburse Sanofi for 30%–50% of worldwide development expenses that were funded by Sanofi (collectively, the ""development balance"") based on our share of collaboration profits from commercialization of collaboration products.",30%–50%,PERCENT,We are obligated to reimburse Sanofi for 30%–50% of worldwide development expenses that were funded by Sanofi  based on our share of collaboration profits from commercialization of collaboration products.,"['30%–50 % of worldwide development expenses', 'share of collaboration profits', 'share from commercialization', 'commercialization of collaboration products', 'worldwide development expenses', 'collaboration profits', 'collaboration products']","['worldwide development expenses', 0.8294243216514587, 'What is 30%–50% ?', 'worldwide development expenses']",worldwide development expenses,0.8294243216514587,What is 30%–50% ?,worldwide development expenses,Worldwide development expenses
26,"The Company is party to a global, strategic collaboration with Sanofi to research, develop, and commercialize fully human monoclonal antibodies (the ""Antibody Collaboration""), which currently consists of Dupixent, Kevzara, and itepekimab. Under the terms of the Antibody License and Collaboration Agreement (""LCA""), Sanofi is generally responsible for funding 80%–100% of agreed upon development costs. We are obligated to reimburse Sanofi for 30%–50% of worldwide development expenses that were funded by Sanofi (collectively, the ""development balance"") based on our share of collaboration profits from commercialization of collaboration products. However, we are only required to apply 10% of our share of the profits from the Antibody Collaboration in any calendar quarter to reimburse Sanofi for these development costs. The Company's contingent reimbursement obligation to Sanofi under the Antibody Collaboration was approximately $3.103 billion as of December 31, 2020.",50,['Percentage of repayment of development balance out of profits'],regn_PercentageOfRepaymentOfDevelopmentBalanceOutOfProfits,percentItemType,regn,"We are obligated to reimburse Sanofi for 30%–50% of worldwide development expenses that were funded by Sanofi (collectively, the ""development balance"") based on our share of collaboration profits from commercialization of collaboration products.",30%–50%,PERCENT,We are obligated to reimburse Sanofi for 30%–50% of worldwide development expenses that were funded by Sanofi  based on our share of collaboration profits from commercialization of collaboration products.,"['30%–50 % of worldwide development expenses', 'share of collaboration profits', 'share from commercialization', 'commercialization of collaboration products', 'worldwide development expenses', 'collaboration profits', 'collaboration products']","['worldwide development expenses', 0.8294243216514587, 'What is 30%–50% ?', 'worldwide development expenses']",worldwide development expenses,0.8294243216514587,What is 30%–50% ?,worldwide development expenses,worldwide development expenses
27,"The Company is party to a global, strategic collaboration with Sanofi to research, develop, and commercialize fully human monoclonal antibodies (the ""Antibody Collaboration""), which currently consists of Dupixent, Kevzara, and itepekimab. Under the terms of the Antibody License and Collaboration Agreement (""LCA""), Sanofi is generally responsible for funding 80%–100% of agreed upon development costs. We are obligated to reimburse Sanofi for 30%–50% of worldwide development expenses that were funded by Sanofi (collectively, the ""development balance"") based on our share of collaboration profits from commercialization of collaboration products. However, we are only required to apply 10% of our share of the profits from the Antibody Collaboration in any calendar quarter to reimburse Sanofi for these development costs. The Company's contingent reimbursement obligation to Sanofi under the Antibody Collaboration was approximately $3.103 billion as of December 31, 2020.",3.103,['Contingent reimbursement obligation'],regn_ContingentReimbursementObligation,monetaryItemType,regn,"The Company's contingent reimbursement obligation to Sanofi under the Antibody Collaboration was approximately $3.103 billion as of December 31, 2020.",approximately $3.103 billion,MONEY,"The Company's contingent reimbursement obligation to Sanofi under the Antibody Collaboration was approximately $3.103 billion as of December 31, 2020.","['contingent reimbursement obligation to Sanofi', 'contingent reimbursement obligation under Antibody Collaboration', 'contingent reimbursement obligation']","['contingent reimbursement obligation', 0.11368867754936218, 'What is approximately $3.103 billion ?', 'contingent reimbursement obligation']",contingent reimbursement obligation,0.1136886775493621,What is approximately $3.103 billion ?,contingent reimbursement obligation,The Company's contingent reimbursement obligation to Sanofi under the Antibody Collaboration
28,"Regeneron is obligated to use commercially reasonable efforts to supply clinical requirements of each drug candidate under the Antibody Collaboration until commercial supplies of that drug candidate are being manufactured. Sanofi leads commercialization activities for products under the Antibody Collaboration, subject to the Company's right to co commercialize such products. The Company co commercializes Dupixent in the United States and exercised its option to co commercialize Dupixent in certain countries outside the United States. We currently anticipate commencing co commercialization of Dupixent in such countries outside the United States in 2021. The parties equally share profits and losses from sales within the United States. The parties share profits outside the United States on a sliding scale based on sales starting at 65% (Sanofi)/35% (Regeneron) and ending at 55% (Sanofi)/45% (Regeneron), and losses outside the United States at 55% (Sanofi)/45% (Regeneron).",65,"['Starting share of profits outside the United States, based on sales, for collaborating party']",regn_StartingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCollaboratingParty,percentItemType,regn,"The parties share profits outside the United States on a sliding scale based on sales starting at 65% (Sanofi)/35% (Regeneron) and ending at 55% (Sanofi)/45% (Regeneron), and losses outside the United States at 55% (Sanofi)/45% (Regeneron).",65%,PERCENT,"The parties share profits outside the United States on a sliding scale based on sales starting at 65% 35%  and ending at 55% 45% , and losses outside the United States at 55% 45% .","['losses outside United States', 'losses at %']","['', 0, '', '']",,0.0,,,Parties share profits outside United States
29,"Regeneron is obligated to use commercially reasonable efforts to supply clinical requirements of each drug candidate under the Antibody Collaboration until commercial supplies of that drug candidate are being manufactured. Sanofi leads commercialization activities for products under the Antibody Collaboration, subject to the Company's right to co commercialize such products. The Company co commercializes Dupixent in the United States and exercised its option to co commercialize Dupixent in certain countries outside the United States. We currently anticipate commencing co commercialization of Dupixent in such countries outside the United States in 2021. The parties equally share profits and losses from sales within the United States. The parties share profits outside the United States on a sliding scale based on sales starting at 65% (Sanofi)/35% (Regeneron) and ending at 55% (Sanofi)/45% (Regeneron), and losses outside the United States at 55% (Sanofi)/45% (Regeneron).",35,"['Starting share of profits outside the United States, based on sales, for company']",regn_StartingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCompany,percentItemType,regn,"The parties share profits outside the United States on a sliding scale based on sales starting at 65% (Sanofi)/35% (Regeneron) and ending at 55% (Sanofi)/45% (Regeneron), and losses outside the United States at 55% (Sanofi)/45% (Regeneron).",35%,PERCENT,"The parties share profits outside the United States on a sliding scale based on sales starting at 65% 35%  and ending at 55% 45% , and losses outside the United States at 55% 45% .","['losses outside United States', 'losses at %']","['', 0, '', '']",,0.0,,,Sliding scale based on sales
30,"Regeneron is obligated to use commercially reasonable efforts to supply clinical requirements of each drug candidate under the Antibody Collaboration until commercial supplies of that drug candidate are being manufactured. Sanofi leads commercialization activities for products under the Antibody Collaboration, subject to the Company's right to co commercialize such products. The Company co commercializes Dupixent in the United States and exercised its option to co commercialize Dupixent in certain countries outside the United States. We currently anticipate commencing co commercialization of Dupixent in such countries outside the United States in 2021. The parties equally share profits and losses from sales within the United States. The parties share profits outside the United States on a sliding scale based on sales starting at 65% (Sanofi)/35% (Regeneron) and ending at 55% (Sanofi)/45% (Regeneron), and losses outside the United States at 55% (Sanofi)/45% (Regeneron).",55,"['Ending share of profits outside the United States, based on sales, for collaborating party']",regn_EndingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCollaboratingParty,percentItemType,regn,"The parties share profits outside the United States on a sliding scale based on sales starting at 65% (Sanofi)/35% (Regeneron) and ending at 55% (Sanofi)/45% (Regeneron), and losses outside the United States at 55% (Sanofi)/45% (Regeneron).",55%,PERCENT,"The parties share profits outside the United States on a sliding scale based on sales starting at 65% 35%  and ending at 55% 45% , and losses outside the United States at 55% 45% .","['losses outside United States', 'losses at %']","['losses outside United States', 0.9321619868278503, 'what is losses outside United States ?', '55% 45%']",losses outside United States,0.9321619868278505,what is losses outside United States ?,55% 45%,"Sliding scale profits
Entity: 
45%
Phrase: 
Sliding scale losses"
31,"Regeneron is obligated to use commercially reasonable efforts to supply clinical requirements of each drug candidate under the Antibody Collaboration until commercial supplies of that drug candidate are being manufactured. Sanofi leads commercialization activities for products under the Antibody Collaboration, subject to the Company's right to co commercialize such products. The Company co commercializes Dupixent in the United States and exercised its option to co commercialize Dupixent in certain countries outside the United States. We currently anticipate commencing co commercialization of Dupixent in such countries outside the United States in 2021. The parties equally share profits and losses from sales within the United States. The parties share profits outside the United States on a sliding scale based on sales starting at 65% (Sanofi)/35% (Regeneron) and ending at 55% (Sanofi)/45% (Regeneron), and losses outside the United States at 55% (Sanofi)/45% (Regeneron).",45,"['Ending share of profits outside the United States, based on sales, for company']",regn_EndingShareOfProfitsOutsideUnitedStatesBasedOnSalesForCompany,percentItemType,regn,"The parties share profits outside the United States on a sliding scale based on sales starting at 65% (Sanofi)/35% (Regeneron) and ending at 55% (Sanofi)/45% (Regeneron), and losses outside the United States at 55% (Sanofi)/45% (Regeneron).",45%,PERCENT,"The parties share profits outside the United States on a sliding scale based on sales starting at 65% 35%  and ending at 55% 45% , and losses outside the United States at 55% 45% .","['losses outside United States', 'losses at %']","['losses outside United States', 0.9321619868278503, 'what is losses outside United States ?', '55% 45%']",losses outside United States,0.9321619868278505,what is losses outside United States ?,55% 45%,losses outside the United States
32,"Regeneron is obligated to use commercially reasonable efforts to supply clinical requirements of each drug candidate under the Antibody Collaboration until commercial supplies of that drug candidate are being manufactured. Sanofi leads commercialization activities for products under the Antibody Collaboration, subject to the Company's right to co commercialize such products. The Company co commercializes Dupixent in the United States and exercised its option to co commercialize Dupixent in certain countries outside the United States. We currently anticipate commencing co commercialization of Dupixent in such countries outside the United States in 2021. The parties equally share profits and losses from sales within the United States. The parties share profits outside the United States on a sliding scale based on sales starting at 65% (Sanofi)/35% (Regeneron) and ending at 55% (Sanofi)/45% (Regeneron), and losses outside the United States at 55% (Sanofi)/45% (Regeneron).",55,"['Share of losses outside the United States, for collaborating party']",regn_ShareOfLossesOutsideUnitedStatesForCollaboratingParty,percentItemType,regn,"The parties share profits outside the United States on a sliding scale based on sales starting at 65% (Sanofi)/35% (Regeneron) and ending at 55% (Sanofi)/45% (Regeneron), and losses outside the United States at 55% (Sanofi)/45% (Regeneron).",55%,PERCENT,"The parties share profits outside the United States on a sliding scale based on sales starting at 65% 35%  and ending at 55% 45% , and losses outside the United States at 55% 45% .","['losses outside United States', 'losses at %']","['losses outside United States', 0.9321619868278503, 'what is losses outside United States ?', '55% 45%']",losses outside United States,0.9321619868278505,what is losses outside United States ?,55% 45%,Share profits United States
33,"Regeneron is obligated to use commercially reasonable efforts to supply clinical requirements of each drug candidate under the Antibody Collaboration until commercial supplies of that drug candidate are being manufactured. Sanofi leads commercialization activities for products under the Antibody Collaboration, subject to the Company's right to co commercialize such products. The Company co commercializes Dupixent in the United States and exercised its option to co commercialize Dupixent in certain countries outside the United States. We currently anticipate commencing co commercialization of Dupixent in such countries outside the United States in 2021. The parties equally share profits and losses from sales within the United States. The parties share profits outside the United States on a sliding scale based on sales starting at 65% (Sanofi)/35% (Regeneron) and ending at 55% (Sanofi)/45% (Regeneron), and losses outside the United States at 55% (Sanofi)/45% (Regeneron).",45,"['Share of losses outside the United States, for company']",regn_ShareOfLossesOutsideUnitedStatesForCompany,percentItemType,regn,"The parties share profits outside the United States on a sliding scale based on sales starting at 65% (Sanofi)/35% (Regeneron) and ending at 55% (Sanofi)/45% (Regeneron), and losses outside the United States at 55% (Sanofi)/45% (Regeneron).",45%,PERCENT,"The parties share profits outside the United States on a sliding scale based on sales starting at 65% 35%  and ending at 55% 45% , and losses outside the United States at 55% 45% .","['losses outside United States', 'losses at %']","['losses outside United States', 0.9321619868278503, 'what is losses outside United States ?', '55% 45%']",losses outside United States,0.9321619868278505,what is losses outside United States ?,55% 45%,sliding scale based on sales
34,"In addition to profit and loss sharing, we are entitled to receive sales milestone payments from Sanofi. In the third quarter of 2020, the Company earned, and recognized as revenue, the first $50.0 million sales based milestone from Sanofi, upon aggregate annual sales of Dupixent, Kevzara, and Praluent outside the United States exceeding $1.0 billion on a rolling twelve month basis. We are entitled to receive up to an aggregate of $200.0 million in additional milestone payments from Sanofi, including the second sales milestone in the amount of $50.0 million, when such sales outside the United States exceed $1.5 billion on a rolling twelve month basis.",50.0,['Revenues'],us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax,monetaryItemType,regn,"In the third quarter of 2020, the Company earned, and recognized as revenue, the first $50.0 million sales based milestone from Sanofi, upon aggregate annual sales of Dupixent, Kevzara, and Praluent outside the United States exceeding $1.0 billion on a rolling twelve month basis.",$50.0 million,MONEY,"In the third quarter of 2020, the Company earned, and recognized as revenue, the first $50.0 million sales based milestone from Sanofi, upon aggregate annual sales of Dupixent, Kevzara, and Praluent outside the United States exceeding $1.0 billion on a rolling twelve month basis.","['based milestone from Sanofi', 'aggregate annual sales of Dupixent', 'aggregate annual sales', 'rolling month basis']","['sales based milestone', 0.46610909700393677, 'What is $50.0 million ?', 'sales based milestone']",sales based milestone,0.4661090970039367,What is $50.0 million ?,sales based milestone,First sales-based milestone from Sanofi
35,"In addition to profit and loss sharing, we are entitled to receive sales milestone payments from Sanofi. In the third quarter of 2020, the Company earned, and recognized as revenue, the first $50.0 million sales based milestone from Sanofi, upon aggregate annual sales of Dupixent, Kevzara, and Praluent outside the United States exceeding $1.0 billion on a rolling twelve month basis. We are entitled to receive up to an aggregate of $200.0 million in additional milestone payments from Sanofi, including the second sales milestone in the amount of $50.0 million, when such sales outside the United States exceed $1.5 billion on a rolling twelve month basis.",1.0,['Levels of twelve month sales at which sales milestone payments would be received'],regn_Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswouldbereceived,monetaryItemType,regn,"In the third quarter of 2020, the Company earned, and recognized as revenue, the first $50.0 million sales based milestone from Sanofi, upon aggregate annual sales of Dupixent, Kevzara, and Praluent outside the United States exceeding $1.0 billion on a rolling twelve month basis.",$1.0 billion,MONEY,"In the third quarter of 2020, the Company earned, and recognized as revenue, the first $50.0 million sales based milestone from Sanofi, upon aggregate annual sales of Dupixent, Kevzara, and Praluent outside the United States exceeding $1.0 billion on a rolling twelve month basis.","['based milestone from Sanofi', 'aggregate annual sales of Dupixent', 'aggregate annual sales', 'rolling month basis']","['aggregate annual sales of Dupixent', 0.5987862944602966, 'what is aggregate annual sales of Dupixent ?', '$1.0 billion']",aggregate annual sales of Dupixent,0.5987862944602966,what is aggregate annual sales of Dupixent ?,$1.0 billion,Sales milestone from Sanofi
36,"In addition to profit and loss sharing, we are entitled to receive sales milestone payments from Sanofi. In the third quarter of 2020, the Company earned, and recognized as revenue, the first $50.0 million sales based milestone from Sanofi, upon aggregate annual sales of Dupixent, Kevzara, and Praluent outside the United States exceeding $1.0 billion on a rolling twelve month basis. We are entitled to receive up to an aggregate of $200.0 million in additional milestone payments from Sanofi, including the second sales milestone in the amount of $50.0 million, when such sales outside the United States exceed $1.5 billion on a rolling twelve month basis.",twelve month,"['Period for achieving sales target for milestone payment, rolling basis']",regn_PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis,durationItemType,regn,"In the third quarter of 2020, the Company earned, and recognized as revenue, the first $50.0 million sales based milestone from Sanofi, upon aggregate annual sales of Dupixent, Kevzara, and Praluent outside the United States exceeding $1.0 billion on a rolling twelve month basis.",twelve month,DATE,"In the third quarter of 2020, the Company earned, and recognized as revenue, the first $50.0 million sales based milestone from Sanofi, upon aggregate annual sales of Dupixent, Kevzara, and Praluent outside the United States exceeding $1.0 billion on a rolling twelve month basis.","['based milestone from Sanofi', 'aggregate annual sales of Dupixent', 'aggregate annual sales', 'rolling month basis']","['rolling', 0.7697129249572754, 'What is twelve month ?', 'rolling']",rolling,0.7697129249572754,What is twelve month ?,rolling,rolling twelve month basis
37,"In addition to profit and loss sharing, we are entitled to receive sales milestone payments from Sanofi. In the third quarter of 2020, the Company earned, and recognized as revenue, the first $50.0 million sales based milestone from Sanofi, upon aggregate annual sales of Dupixent, Kevzara, and Praluent outside the United States exceeding $1.0 billion on a rolling twelve month basis. We are entitled to receive up to an aggregate of $200.0 million in additional milestone payments from Sanofi, including the second sales milestone in the amount of $50.0 million, when such sales outside the United States exceed $1.5 billion on a rolling twelve month basis.",200.0,['Remaining amount of sales milestone payments if total sales achieve specific levels'],regn_RemainingAmountOfSalesMilestonePaymentsIfTotalSalesAchieveSpecificLevels,monetaryItemType,regn,"We are entitled to receive up to an aggregate of $200.0 million in additional milestone payments from Sanofi, including the second sales milestone in the amount of $50.0 million, when such sales outside the United States exceed $1.5 billion on a rolling twelve month basis.",$200.0 million,MONEY,"We are entitled to receive up to an aggregate of $200.0 million in additional milestone payments from Sanofi, including the second sales milestone in the amount of $50.0 million, when such sales outside the United States exceed $1.5 billion on a rolling twelve month basis.","['aggregate', 'additional milestone payments from Sanofi', 'second sales milestone in amount', 'amount', 'such sales outside United States', 'additional milestone payments', 'second sales milestone', 'such sales', 'rolling month basis']","['aggregate', 0.9073963761329651, 'what is aggregate ?', '$200.0 million']",aggregate,0.9073963761329652,what is aggregate ?,$200.0 million,Additional milestone payments from Sanofi
38,"In addition to profit and loss sharing, we are entitled to receive sales milestone payments from Sanofi. In the third quarter of 2020, the Company earned, and recognized as revenue, the first $50.0 million sales based milestone from Sanofi, upon aggregate annual sales of Dupixent, Kevzara, and Praluent outside the United States exceeding $1.0 billion on a rolling twelve month basis. We are entitled to receive up to an aggregate of $200.0 million in additional milestone payments from Sanofi, including the second sales milestone in the amount of $50.0 million, when such sales outside the United States exceed $1.5 billion on a rolling twelve month basis.",50.0,['Sales milestone payment if total sales achieve specific levels'],regn_SalesMilestonePaymentIfTotalSalesAchieveSpecificLevels,monetaryItemType,regn,"In the third quarter of 2020, the Company earned, and recognized as revenue, the first $50.0 million sales based milestone from Sanofi, upon aggregate annual sales of Dupixent, Kevzara, and Praluent outside the United States exceeding $1.0 billion on a rolling twelve month basis.",$50.0 million,MONEY,"In the third quarter of 2020, the Company earned, and recognized as revenue, the first $50.0 million sales based milestone from Sanofi, upon aggregate annual sales of Dupixent, Kevzara, and Praluent outside the United States exceeding $1.0 billion on a rolling twelve month basis.","['based milestone from Sanofi', 'aggregate annual sales of Dupixent', 'aggregate annual sales', 'rolling month basis']","['sales based milestone', 0.46610909700393677, 'What is $50.0 million ?', 'sales based milestone']",sales based milestone,0.4661090970039367,What is $50.0 million ?,sales based milestone,First sales milestone
39,"In addition to profit and loss sharing, we are entitled to receive sales milestone payments from Sanofi. In the third quarter of 2020, the Company earned, and recognized as revenue, the first $50.0 million sales based milestone from Sanofi, upon aggregate annual sales of Dupixent, Kevzara, and Praluent outside the United States exceeding $1.0 billion on a rolling twelve month basis. We are entitled to receive up to an aggregate of $200.0 million in additional milestone payments from Sanofi, including the second sales milestone in the amount of $50.0 million, when such sales outside the United States exceed $1.5 billion on a rolling twelve month basis.",1.5,['Levels of twelve month sales at which sales milestone payments would be received'],regn_Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswouldbereceived,monetaryItemType,regn,"We are entitled to receive up to an aggregate of $200.0 million in additional milestone payments from Sanofi, including the second sales milestone in the amount of $50.0 million, when such sales outside the United States exceed $1.5 billion on a rolling twelve month basis.",$1.5 billion,MONEY,"We are entitled to receive up to an aggregate of $200.0 million in additional milestone payments from Sanofi, including the second sales milestone in the amount of $50.0 million, when such sales outside the United States exceed $1.5 billion on a rolling twelve month basis.","['aggregate', 'additional milestone payments from Sanofi', 'second sales milestone in amount', 'amount', 'such sales outside United States', 'additional milestone payments', 'second sales milestone', 'such sales', 'rolling month basis']","['such sales outside United States', 0.6702228784561157, 'what is such sales outside United States ?', 'exceed $1.5 billion']",such sales outside United States,0.6702228784561157,what is such sales outside United States ?,exceed $1.5 billion,Sales milestone
40,"In addition to profit and loss sharing, we are entitled to receive sales milestone payments from Sanofi. In the third quarter of 2020, the Company earned, and recognized as revenue, the first $50.0 million sales based milestone from Sanofi, upon aggregate annual sales of Dupixent, Kevzara, and Praluent outside the United States exceeding $1.0 billion on a rolling twelve month basis. We are entitled to receive up to an aggregate of $200.0 million in additional milestone payments from Sanofi, including the second sales milestone in the amount of $50.0 million, when such sales outside the United States exceed $1.5 billion on a rolling twelve month basis.",twelve month,"['Period for achieving sales target for milestone payment, rolling basis']",regn_PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis,durationItemType,regn,"In the third quarter of 2020, the Company earned, and recognized as revenue, the first $50.0 million sales based milestone from Sanofi, upon aggregate annual sales of Dupixent, Kevzara, and Praluent outside the United States exceeding $1.0 billion on a rolling twelve month basis.",twelve month,DATE,"In the third quarter of 2020, the Company earned, and recognized as revenue, the first $50.0 million sales based milestone from Sanofi, upon aggregate annual sales of Dupixent, Kevzara, and Praluent outside the United States exceeding $1.0 billion on a rolling twelve month basis.","['based milestone from Sanofi', 'aggregate annual sales of Dupixent', 'aggregate annual sales', 'rolling month basis']","['rolling', 0.7697129249572754, 'What is twelve month ?', 'rolling']",rolling,0.7697129249572754,What is twelve month ?,rolling,annual sales
41,"In April 2020, the Company and Sanofi entered into an amendment to the LCA in connection with, among other things, the removal of Praluent from the LCA such that (i) effective April 1, 2020, the LCA no longer governs the development, manufacture, or commercialization of Praluent and (ii) the quarterly period ended March 31, 2020 was the last quarter for which Sanofi and the Company shared profits and losses for Praluent under the LCA. The parties also entered into a Praluent Cross License & Commercialization Agreement (the ""Praluent Agreement"") pursuant to which, effective April 1, 2020, the Company, at its sole cost, is solely responsible for the development and commercialization of Praluent in the United States, and Sanofi, at its sole cost, is solely responsible for the development and commercialization of Praluent outside of the United States. Under the Praluent Agreement, Sanofi will pay the Company a 5% royalty on Sanofi's net product sales of Praluent outside the United States until March 31, 2032. The Company will not owe Sanofi royalties on the Company's net product sales of Praluent in the United States. Although each party will be responsible for manufacturing Praluent for its respective territory, the parties have entered into definitive supply agreements under which, for a certain transitional period, the Company will continue to supply drug substance to Sanofi and Sanofi will continue to supply finished product to Regeneron. With respect to any intellectual property or product liability litigation relating to Praluent, the parties have agreed that, effective April 1, 2020, Regeneron and Sanofi each will be solely responsible for any such litigation (including damages and other costs and expenses thereof) in the United States and outside the United States, respectively, arising out of Praluent sales or other activities on or after April 1, 2020 (subject to Sanofi's right to set off a portion of any third party royalty payments resulting from certain patent litigation proceedings against up to 50% of any Praluent royalty payment owed to Regeneron). The parties will each bear 50% of any damages arising out of Praluent sales or other activities prior to April 1, 2020. See Note 15 for discussion of legal proceedings related to Praluent.",5,['Royalty percentage to be received on net product sales outside of the United States'],regn_RoyaltyPercentageToBeReceivedOnNetProductSalesOutsideOfUnitedStates,percentItemType,regn,"Under the Praluent Agreement, Sanofi will pay the Company a 5% royalty on Sanofi’s net product sales of Praluent outside the United States until March 31, 2032.",5%,PERCENT,"Under the Praluent Agreement, Sanofi will pay the Company a 5% royalty on Sanofi’s net product sales of Praluent outside the United States until March 31, 2032.","['% royalty on net product sales', 'net product sales of Praluent', 'net product sales outside United States', '% royalty', 'net product sales']","['% royalty on net product sales', 0.8216632604598999, 'what is % royalty on net product sales ?', '5%']",% royalty on net product sales,0.8216632604598999,what is % royalty on net product sales ?,5%,Sanofi's net product sales
42,"In April 2020, the Company and Sanofi entered into an amendment to the LCA in connection with, among other things, the removal of Praluent from the LCA such that (i) effective April 1, 2020, the LCA no longer governs the development, manufacture, or commercialization of Praluent and (ii) the quarterly period ended March 31, 2020 was the last quarter for which Sanofi and the Company shared profits and losses for Praluent under the LCA. The parties also entered into a Praluent Cross License & Commercialization Agreement (the ""Praluent Agreement"") pursuant to which, effective April 1, 2020, the Company, at its sole cost, is solely responsible for the development and commercialization of Praluent in the United States, and Sanofi, at its sole cost, is solely responsible for the development and commercialization of Praluent outside of the United States. Under the Praluent Agreement, Sanofi will pay the Company a 5% royalty on Sanofi's net product sales of Praluent outside the United States until March 31, 2032. The Company will not owe Sanofi royalties on the Company's net product sales of Praluent in the United States. Although each party will be responsible for manufacturing Praluent for its respective territory, the parties have entered into definitive supply agreements under which, for a certain transitional period, the Company will continue to supply drug substance to Sanofi and Sanofi will continue to supply finished product to Regeneron. With respect to any intellectual property or product liability litigation relating to Praluent, the parties have agreed that, effective April 1, 2020, Regeneron and Sanofi each will be solely responsible for any such litigation (including damages and other costs and expenses thereof) in the United States and outside the United States, respectively, arising out of Praluent sales or other activities on or after April 1, 2020 (subject to Sanofi's right to set off a portion of any third party royalty payments resulting from certain patent litigation proceedings against up to 50% of any Praluent royalty payment owed to Regeneron). The parties will each bear 50% of any damages arising out of Praluent sales or other activities prior to April 1, 2020. See Note 15 for discussion of legal proceedings related to Praluent.",50,['Percentage of royalty payment that can be used to offset litigation proceedings'],regn_PercentageOfRoyaltyPaymentThatCanBeOffset,percentItemType,regn,"With respect to any intellectual property or product liability litigation relating to Praluent, the parties have agreed that, effective April 1, 2020, Regeneron and Sanofi each will be solely responsible for any such litigation (including damages and other costs and expenses thereof) in the United States and outside the United States, respectively, arising out of Praluent sales or other activities on or after April 1, 2020 (subject to Sanofi's right to set off a portion of any third party royalty payments resulting from certain patent litigation proceedings against up to 50% of any Praluent royalty payment owed to Regeneron).",up to 50%,PERCENT,"With respect to any intellectual property or product liability litigation relating to Praluent, the parties have agreed that, effective April 1, 2020, Regeneron and Sanofi each will be solely responsible for any such litigation  in the United States and outside the United States, respectively, arising out of Praluent sales or other activities on or after April 1, 2020 subject to Sanofi's right to set off a portion of any third party royalty payments resulting from certain patent litigation proceedings against up to 50% of any Praluent royalty payment owed to Regeneron.","['respect to liability litigation', 'such litigation in United States', 'subject to right', 'portion of party royalty payments', 'certain litigation proceedings against %', '% of Praluent royalty payment', 'liability litigation', 'such litigation', 'Praluent sales', 'party royalty payments', 'certain litigation proceedings', 'Praluent royalty payment']","['party royalty payments', 0.07276343554258347, 'what is party royalty payments ?', 'up to 50%']",party royalty payments,0.0727634355425834,what is party royalty payments ?,up to 50%,right to set off a portion
43,"In April 2020, the Company and Sanofi entered into an amendment to the LCA in connection with, among other things, the removal of Praluent from the LCA such that (i) effective April 1, 2020, the LCA no longer governs the development, manufacture, or commercialization of Praluent and (ii) the quarterly period ended March 31, 2020 was the last quarter for which Sanofi and the Company shared profits and losses for Praluent under the LCA. The parties also entered into a Praluent Cross License & Commercialization Agreement (the ""Praluent Agreement"") pursuant to which, effective April 1, 2020, the Company, at its sole cost, is solely responsible for the development and commercialization of Praluent in the United States, and Sanofi, at its sole cost, is solely responsible for the development and commercialization of Praluent outside of the United States. Under the Praluent Agreement, Sanofi will pay the Company a 5% royalty on Sanofi's net product sales of Praluent outside the United States until March 31, 2032. The Company will not owe Sanofi royalties on the Company's net product sales of Praluent in the United States. Although each party will be responsible for manufacturing Praluent for its respective territory, the parties have entered into definitive supply agreements under which, for a certain transitional period, the Company will continue to supply drug substance to Sanofi and Sanofi will continue to supply finished product to Regeneron. With respect to any intellectual property or product liability litigation relating to Praluent, the parties have agreed that, effective April 1, 2020, Regeneron and Sanofi each will be solely responsible for any such litigation (including damages and other costs and expenses thereof) in the United States and outside the United States, respectively, arising out of Praluent sales or other activities on or after April 1, 2020 (subject to Sanofi's right to set off a portion of any third party royalty payments resulting from certain patent litigation proceedings against up to 50% of any Praluent royalty payment owed to Regeneron). The parties will each bear 50% of any damages arising out of Praluent sales or other activities prior to April 1, 2020. See Note 15 for discussion of legal proceedings related to Praluent.",50,['Percentage of damages company is responsible for'],regn_LossContingencyPercentageOfDamagesResponsibleFor,percentItemType,regn,"With respect to any intellectual property or product liability litigation relating to Praluent, the parties have agreed that, effective April 1, 2020, Regeneron and Sanofi each will be solely responsible for any such litigation (including damages and other costs and expenses thereof) in the United States and outside the United States, respectively, arising out of Praluent sales or other activities on or after April 1, 2020 (subject to Sanofi's right to set off a portion of any third party royalty payments resulting from certain patent litigation proceedings against up to 50% of any Praluent royalty payment owed to Regeneron).",up to 50%,PERCENT,"With respect to any intellectual property or product liability litigation relating to Praluent, the parties have agreed that, effective April 1, 2020, Regeneron and Sanofi each will be solely responsible for any such litigation  in the United States and outside the United States, respectively, arising out of Praluent sales or other activities on or after April 1, 2020 subject to Sanofi's right to set off a portion of any third party royalty payments resulting from certain patent litigation proceedings against up to 50% of any Praluent royalty payment owed to Regeneron.","['respect to liability litigation', 'such litigation in United States', 'subject to right', 'portion of party royalty payments', 'certain litigation proceedings against %', '% of Praluent royalty payment', 'liability litigation', 'such litigation', 'Praluent sales', 'party royalty payments', 'certain litigation proceedings', 'Praluent royalty payment']","['party royalty payments', 0.07276343554258347, 'what is party royalty payments ?', 'up to 50%']",party royalty payments,0.0727634355425834,what is party royalty payments ?,up to 50%,third party royalty payments
44,"The Company is party to a collaboration with Sanofi to research, develop, and commercialize antibody based cancer treatments in the field of immuno oncology (the ""IO Collaboration""). The IO Collaboration is governed by an Amended and Restated Immuno oncology Discovery and Development Agreement (""Amended IO Discovery Agreement""), and an Immuno oncology License and Collaboration Agreement (""IO License and Collaboration Agreement""). In connection with the execution of the original Immuno oncology Discovery and Development Agreement in 2015 (""2015 IO Discovery Agreement""), which has been replaced by the Amended IO Discovery Agreement (as discussed below), Sanofi made a $265.0 million non refundable up front payment to the Company. Pursuant to the 2015 IO Discovery Agreement, the Company was to spend up to $1.090 billion to identify and validate potential immuno oncology targets and develop therapeutic antibodies against such targets through clinical proof of concept, and Sanofi was to reimburse the Company for up to $825.0 million of these costs, subject to certain annual limits.",265.0,['Up front payment received'],regn_UpFrontPaymentReceived,monetaryItemType,regn,"In connection with the execution of the original Immuno oncology Discovery and Development Agreement in 2015 (""2015 IO Discovery Agreement""), which has been replaced by the Amended IO Discovery Agreement (as discussed below), Sanofi made a $265.0 million non refundable up front payment to the Company.",$265.0 million,MONEY,"In connection with the execution of the original Immuno oncology Discovery and Development Agreement in 2015 ""2015 IO Discovery Agreement"", which has been replaced by the Amended IO Discovery Agreement , Sanofi made a $265.0 million non refundable up front payment to the Company.","['connection with execution', 'execution of original Agreement', 'execution in IO Discovery Agreement', 'refundable front payment to Company', 'original Agreement', 'IO Discovery Agreement', 'IO Discovery Agreement', 'refundable front payment']","['refundable front payment', 0.9811185002326965, 'what is refundable front payment ?', '$265.0 million']",refundable front payment,0.9811185002326964,what is refundable front payment ?,$265.0 million,Original Immuno oncology Discovery and Development Agreement
45,"The Company is party to a collaboration with Sanofi to research, develop, and commercialize antibody based cancer treatments in the field of immuno oncology (the ""IO Collaboration""). The IO Collaboration is governed by an Amended and Restated Immuno oncology Discovery and Development Agreement (""Amended IO Discovery Agreement""), and an Immuno oncology License and Collaboration Agreement (""IO License and Collaboration Agreement""). In connection with the execution of the original Immuno oncology Discovery and Development Agreement in 2015 (""2015 IO Discovery Agreement""), which has been replaced by the Amended IO Discovery Agreement (as discussed below), Sanofi made a $265.0 million non refundable up front payment to the Company. Pursuant to the 2015 IO Discovery Agreement, the Company was to spend up to $1.090 billion to identify and validate potential immuno oncology targets and develop therapeutic antibodies against such targets through clinical proof of concept, and Sanofi was to reimburse the Company for up to $825.0 million of these costs, subject to certain annual limits.",1.090,['Potential future R&D expenses'],regn_PotentialFutureResearchAndDevelopmentExpenses,monetaryItemType,regn,"Pursuant to the 2015 IO Discovery Agreement, the Company was to spend up to $1.090 billion to identify and validate potential immuno oncology targets and develop therapeutic antibodies against such targets through clinical proof of concept, and Sanofi was to reimburse the Company for up to $825.0 million of these costs, subject to certain annual limits.",up to $1.090 billion,MONEY,"Pursuant to the 2015 IO Discovery Agreement, the Company was to spend up to $1.090 billion to identify and validate potential immuno oncology targets and develop therapeutic antibodies against such targets through clinical proof of concept, and Sanofi was to reimburse the Company for up to $825.0 million of these costs, subject to certain annual limits.","['therapeutic antibodies against such targets', 'clinical proof of concept', 'IO Discovery Agreement', 'potential immuno oncology targets', 'therapeutic antibodies', 'such targets', 'clinical proof', 'certain annual limits']","['to identify and validate potential immuno oncology targets', 0.13935580849647522, 'What is up to $1.090 billion ?', 'to identify and validate potential immuno oncology targets']",to identify and validate potential immuno oncology targets,0.1393558084964752,What is up to $1.090 billion ?,to identify and validate potential immuno oncology targets,to identify and validate potential immuno oncology targets and develop therapeutic antibodies against such targets through clinical proof of concept
46,"The Company is party to a collaboration with Sanofi to research, develop, and commercialize antibody based cancer treatments in the field of immuno oncology (the ""IO Collaboration""). The IO Collaboration is governed by an Amended and Restated Immuno oncology Discovery and Development Agreement (""Amended IO Discovery Agreement""), and an Immuno oncology License and Collaboration Agreement (""IO License and Collaboration Agreement""). In connection with the execution of the original Immuno oncology Discovery and Development Agreement in 2015 (""2015 IO Discovery Agreement""), which has been replaced by the Amended IO Discovery Agreement (as discussed below), Sanofi made a $265.0 million non refundable up front payment to the Company. Pursuant to the 2015 IO Discovery Agreement, the Company was to spend up to $1.090 billion to identify and validate potential immuno oncology targets and develop therapeutic antibodies against such targets through clinical proof of concept, and Sanofi was to reimburse the Company for up to $825.0 million of these costs, subject to certain annual limits.",825.0,['Maximum funding amount of research activities to be reimbursed per agreement'],regn_FundingMaximumOfResearchActivitiesPerAgreement,monetaryItemType,regn,"Pursuant to the 2015 IO Discovery Agreement, the Company was to spend up to $1.090 billion to identify and validate potential immuno oncology targets and develop therapeutic antibodies against such targets through clinical proof of concept, and Sanofi was to reimburse the Company for up to $825.0 million of these costs, subject to certain annual limits.",up to $825.0 million,MONEY,"Pursuant to the 2015 IO Discovery Agreement, the Company was to spend up to $1.090 billion to identify and validate potential immuno oncology targets and develop therapeutic antibodies against such targets through clinical proof of concept, and Sanofi was to reimburse the Company for up to $825.0 million of these costs, subject to certain annual limits.","['therapeutic antibodies against such targets', 'clinical proof of concept', 'IO Discovery Agreement', 'potential immuno oncology targets', 'therapeutic antibodies', 'such targets', 'clinical proof', 'certain annual limits']","['certain annual limits', 0.3944777548313141, 'what is certain annual limits ?', 'up to $825.0 million of these costs']",certain annual limits,0.3944777548313141,what is certain annual limits ?,up to $825.0 million of these costs,2015 IO Discovery Agreement
47,"We are obligated to reimburse Sanofi for half of the development costs they funded that are attributable to clinical development of antibody product candidates from our share of future profits from commercialized IO Collaboration products. However, the Company is only required to apply 10% of its share of the profits from IO Collaboration products in any calendar quarter towards reimbursing Sanofi for these development costs. The Company's contingent reimbursement obligation to Sanofi under the IO Collaboration was approximately $107 million as of December 31, 2020.",10,['Percentage of quarterly profits require to be paid for reimbursement of development costs'],regn_PercentageOfQuarterlyProfitsRequiredToBePaidForReimbursementOfDevelopmentCosts,percentItemType,regn,"However, the Company is only required to apply 10% of its share of the profits from IO Collaboration products in any calendar quarter towards reimbursing Sanofi for these development costs.",apply 10%,PERCENT,"However, the Company is only required to apply 10% of its share of the profits from IO Collaboration products in any calendar quarter towards reimbursing Sanofi for these development costs.","['% of share', 'share of profits', 'profits from IO Collaboration products', 'IO Collaboration products', 'calendar quarter', 'development costs']","['', 0, '', '']",,0.0,,,share of profits
48,"We are obligated to reimburse Sanofi for half of the development costs they funded that are attributable to clinical development of antibody product candidates from our share of future profits from commercialized IO Collaboration products. However, the Company is only required to apply 10% of its share of the profits from IO Collaboration products in any calendar quarter towards reimbursing Sanofi for these development costs. The Company's contingent reimbursement obligation to Sanofi under the IO Collaboration was approximately $107 million as of December 31, 2020.",107,['Contingent reimbursement obligation'],regn_ContingentReimbursementObligation,monetaryItemType,regn,"The Company's contingent reimbursement obligation to Sanofi under the IO Collaboration was approximately $107 million as of December 31, 2020.",approximately $107 million,MONEY,"The Company's contingent reimbursement obligation to Sanofi under the IO Collaboration was approximately $107 million as of December 31, 2020.","['contingent reimbursement obligation to Sanofi', 'contingent reimbursement obligation under IO Collaboration', 'contingent reimbursement obligation']","['contingent reimbursement obligation', 0.36238738894462585, 'What is approximately $107 million ?', 'contingent reimbursement obligation']",contingent reimbursement obligation,0.3623873889446258,What is approximately $107 million ?,contingent reimbursement obligation,The Company's contingent reimbursement obligation to Sanofi under the IO Collaboration
49,"Effective December 31, 2018, the Company and Sanofi entered into the Amended IO Discovery Agreement, which narrowed the scope of the existing discovery and development activities conducted by the Company (""IO Development Activities"") under the 2015 IO Discovery Agreement to developing therapeutic bispecific antibodies targeting (i) BCMA and CD3 (the ""BCMAxCD3 Program"") and (ii) MUC16 and CD3 (the ""MUC16xCD3 Program"") through clinical proof of concept. The Amended IO Discovery Agreement provided for Sanofi's payment of $461.9 million to the Company as consideration for (x) the termination of the 2015 IO Discovery Agreement, (y) the prepayment for certain IO Development Activities regarding the BCMAxCD3 Program and the MUC16xCD3 Program, and (z) the reimbursement of costs incurred by the Company under the 2015 IO Discovery Agreement during the fourth quarter of 2018.",461.9,['Aggregate payment received with regards to amendment'],regn_AggregatePaymentReceivedWithRegardsToAmendment,monetaryItemType,regn,"The Amended IO Discovery Agreement provided for Sanofi’s payment of $461.9 million to the Company as consideration for (x) the termination of the 2015 IO Discovery Agreement, (y) the prepayment for certain IO Development Activities regarding the BCMAxCD3 Program and the MUC16xCD3 Program, and (z) the reimbursement of costs incurred by the Company under the 2015 IO Discovery Agreement during the fourth quarter of 2018.",$461.9 million,MONEY,"The Amended IO Discovery Agreement provided for Sanofi’s payment of $461.9 million to the Company as consideration for  the termination of the 2015 IO Discovery Agreement,  the prepayment for certain IO Development Activities regarding the BCMAxCD3 Program and the MUC16xCD3 Program, and  the reimbursement of costs incurred by the Company under the 2015 IO Discovery Agreement during the fourth quarter of 2018.","['payment', 'payment to Company', 'consideration for termination', 'termination of IO Discovery Agreement', 'prepayment for certain IO Development Activities', 'reimbursement of costs', 'certain IO Development Activities', 'BCMAxCD3 Program']","['payment to Company', 0.9869498610496521, 'what is payment to Company ?', '$461.9 million']",payment to Company,0.986949861049652,what is payment to Company ?,$461.9 million,The Amended IO Discovery Agreement
